A comprehensive view of Immune System Health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
Novavax Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall
Published:
April 26, 2024
by Novavax Inc.
|
US Patent Issued to Bristol-Myers Squibb on April 23 for "Substituted bicyclic compounds useful as T cell activators" (American, Indian Inventors)
Published:
April 24, 2024
by U.S. Fed News
|
US Patent Issued to Amgen on April 23 for "ST2 antigen binding proteins" (American, Canadian Inventors)
Published:
April 24, 2024
by U.S. Fed News
|
US Patent Issued to PFIZER on April 23 for "Modulators of STING (stimulator of interferon genes)" (California, Connecticut Inventors)
Published:
April 24, 2024
by U.S. Fed News
|
Sanofi's rilzabrutinib meets primary endpoint in Phase 3 LUNA 3 study for immune thrombocytopenia; potential for clinically beneficial treatment of several immune diseases underscored, with regulatory submissions in the US and EU expected by year-end
Published:
April 23, 2024
by Sanofi SA
|
Ask us about our Tissue & Hygiene market view